About Properdin
Properdin (CFP) is a protein
from Homo sapiens identified by UniProt accession
P27918, 469 residues long.
MolForge cross-references it against 0 known binders and
313 disease associations.
Target properties
| Protein name | Properdin |
|---|
| UniProt accession | P27918 |
|---|
| Gene | CFP |
|---|
| Organism | Homo sapiens |
|---|
| Length | 469 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (313)
Diseases linked to this target (Open Targets).
- Properdin deficiency · score 0.70
- properdin deficiency, X-linked · score 0.69
- neurodegenerative disease · score 0.29
- head and neck squamous cell carcinoma · score 0.22
- gastric adenocarcinoma · score 0.20
- genetic disorder · score 0.18
- breast adenocarcinoma · score 0.15
- esophageal cancer · score 0.15
- glioblastoma multiforme · score 0.13
- urinary bladder cancer · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P27918-F1 | alphafold | PREDICTED | 83.30 | — |
Amino-acid sequence (469 residues)
MITEGAQAPR LLLPPLLLLL TLPATGSDPV LCFTQYEESS GKCKGLLGGG VSVEDCCLNT AFAYQKRSGG LCQPCRSPRW SLWSTWAPCS VTCSEGSQLR YRRCVGWNGQ CSGKVAPGTL EWQLQACEDQ QCCPEMGGWS GWGPWEPCSV TCSKGTRTRR RACNHPAPKC GGHCPGQAQE SEACDTQQVC PTHGAWATWG PWTPCSASCH GGPHEPKETR SRKCSAPEPS QKPPGKPCPG LAYEQRRCTG LPPCPVAGGW GPWGPVSPCP VTCGLGQTME QRTCNHPVPQ HGGPFCAGDA TRTHICNTAV PCPVDGEWDS WGEWSPCIRR NMKSISCQEI PGQQSRGRTC RGRKFDGHRC AGQQQDIRHC YSIQHCPLKG SWSEWSTWGL CMPPCGPNPT RARQRLCTPL LPKYPPTVSM VEGQGEKNVT FWGRPLPRCE ELQGQKLVVE EKRPCLHVPA CKDPEEEEL
Explore Properdin with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets